Floatz logo

FDOPA

Brain Glioma

University of AlbertaSmall moleculePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Brain Glioma cohort.

Asset / SponsorPhaseRating
Everolimus
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1B
Ganciclovir
Huazhong University of Science and Technology
Phase 2B
Aglatimagene Besadenovec
Huazhong University of Science and Technology
Phase 2B
Ribociclib
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1B
gp96
Cure&Sure Biotech Co., LTD
Phase 2CCC

View all 22 →

Same molecule, other indications

FDOPA is also rated in:

congenital isolated hyperinsulinismActive
BB
Indicative · Phase 3
66 / 100
View asset →
Lewy body dementiaActive
B
Indicative · Phase 3
63 / 100
View asset →
Parkinson diseaseActive
B
Indicative · Phase 3
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →